23 results on '"Friedbichler, Katrin"'
Search Results
2. Supplementary Materials and Methods, Tables 1-2 and Figure Legends from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
3. Supplementary Figure 1 from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
4. Supplementary Methods, Tables and Figures from Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
5. Data from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
6. Supplementary Figure 2 from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
7. Stat5 as a Hematopoietic Master Regulator for Differentiation and Neoplasia Development
8. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation
9. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade
10. Growth-hormone–induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer
11. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice
12. Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
13. STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice
14. Interleukin- 6 and Oncostatin M Stimulation of Proliferation of Prostate Cancer 22Rv1 Cells Through the Signaling Pathways of p38 Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase
15. Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development
16. Abstract 20: Xentuzumab, a humanized IGF-1 and IGF-2 ligand neutralizing antibody, improves the antitumor efficacy of enzalutamide in preclinical models of prostate cancer
17. Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice
18. Abstract 108: Consequences of hepatic JAK2 deficiency for liver metabolism and hepatocarcinogenesis
19. Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
20. Impairment of Hepatic Growth Hormone and Glucocorticoid Receptor Signaling Causes Steatosis and Hepatocellular Carcinoma in Mice
21. BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamycin-induced AKT activation.
22. Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation
23. The different functions of Stat5 and chromatin alteration through Stat5 proteins.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.